dismiss

Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Current Location:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Cardiology Homepage

Leading vascular surgeon presents comparative data analysis on EndoAVF procedures at Society of Interventional Radiology 2019

Intact Vascular’s Tack Endovascular System receives FDA approval

iSchemaView’s RAPID approved for use in the Kingdom of Saudi Arabia

Stryker launches LIFEPAK CR2 defibrillator with LIFELINKcentral AED program manager in the United States

Avinger (AVGR) announces receipt of FDA 510(k) clearance of Pantheris SV device

BIOTRONIK launches PK Papyrus covered coronary stent in the US

Insera earns CE Mark approval for cyclical-suction stroke thrombectomy platform, the CLEAR aspiration system

iSchemaView’s RAPID approved for use in Israel

Seisa Medical announces acquisition of Burpee MedSystems

Study finds lower death rates for TAVR centers that do more procedures

Five-year study data confirm positive outcomes for patients when Abbott diagnostic tool was used to guide heart stenting

Press releases may be edited for formatting or style
PARIS, May 22, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced five-year results from the FAME 2 study, which showed that patients had fewer major adverse cardiac events (MACE) when they received a heart stent guided by Abbott's fractional flow reserve (FFR) diagnostic tool in combination with medical therapy compared to patients who received only medical therapy. MACE is defined as heart attack, death and urgent need to reestablish blood flow. Abbott's PressureWireTM uses the diagnostic metric FFR to measure the pressure of blood as it flows through a patient's blocked artery. This provides an objective measure to help cardiologists determine which vessels would benefit from receiving a stent.

The five-year data from the FAME 2 study were presented in a late-breaking session at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and simultaneously published in The New England Journal of Medicine.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



"For the first time, a study has shown that patients with stable coronary artery disease who received a stent guided by an FFR diagnostic had a benefit over medical therapy alone, including fewer heart attacks and needs for urgent revascularization," said principal investigator Bernard De Bruyne, M.D., Ph.D., of the Cardiovascular Center Aalst, Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium. "Data from this study confirm the importance of FFR-guided stenting decisions combined with medical therapy over medical therapy alone."

Coronary artery disease is the most common type of heart disease, which is the leading cause of death worldwide. It occurs when arteries that supply blood to the heart become blocked or narrowed. Physicians can use an FFR diagnostic tool to measure how a narrowed artery affects blood flow to the heart, and can then determine the appropriate treatment. If a narrowed artery has a positive FFR test, placing a stent via a percutaneous coronary intervention (PCI) is one recommended treatment.

Five-year follow up from the FAME 2 study included 733 patients with stable coronary artery disease who had significant blockages or narrowing of the arteries as determined by FFR. Analysis showed that 13.9 percent of patients (62) in the FFR-guided PCI group experienced a MACE, while almost twice as many patients in the medical therapy group experienced MACE (27 percent (119); p=<0.001). The lower rate of MACE in the PCI group was largely driven by reduced urgent revascularization – the need to reestablish blood flow to the heart – a component of MACE (6.3 percent vs. 21.1 percent, p<0.001).
  Pages: 1 - 2 - 3 >>

Cardiology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED